Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Looks Ahead To Simponi Launch In Canada, Europe After Sluggish Q1

This article was originally published in The Pink Sheet Daily

Executive Summary

Canadian launch of the once-monthly anti-TNF is targeted for the second half; the market represents the first approval for the biologic.

You may also be interested in...



J&J Celebrates Simponi Approval With Schering – For Now

As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.

J&J Celebrates Simponi Approval With Schering – For Now

As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.

Merck Delays Migraine Drug Filing; Q1 Sales Fall Short of Analyst Expectations

Telcagepant approval, next anticipated opportunity in pipeline, at standstill; analysts look to Schering-Plough deal to bolster Merck sales.

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel